Infliximab is a representative mAbs that interacts with target tumor necrosis factor α (TNF-α) for treating autoimmune diseases, such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, adult plaque psoriasis, pediatric and adult ulcerative colitis and Crohn’s disease (Scallon et al., 2002; Willrich et al., 2015) This drug is based on a combination of murine variable regions and the human Fc region of IgG1 expressed in a Sp2/0 cell line. Here, TNF is linked to psoriatic arthritis.